| Literature DB >> 30213035 |
Xiao Zheng1,2, Fei Wu3,4, Yanlong Hong5, Lan Shen6, Xiao Lin7, Yi Feng8.
Abstract
A variety of pharmacologically active substances, including chemotherapeutic drugs and the substances from traditional Chinese medicine (TCM), always exhibit potent bioactivities after oral administration. However, their unpleasant taste (such as bitterness) and/or odor always decrease patient compliance and thus compromise their curative efficacies in clinical application. Therefore, the developments of taste-masking techniques are of great significance in improving their organoleptic properties. However, though a variety of taste-masking techniques have been successfully used to mask the unpalatable taste of chemotherapeutic drugs, their suitability for TCM substances is relatively limited. This is mainly due to the fact that the bitter ingredients existing in multicomponent TCM systems (i.e., effective fractions, single Chinese herbs, and compound preparations) are always unclear, and thus, there is lack of tailor-made taste-masking techniques to be utilized to conceal their unpleasant taste. The relevant studies are also relatively limited. As a whole, three types of taste-masking techniques are generally applied to TCM, including (i) functional masking via sweeteners, bitter blockers, and taste modifiers; (ii) physical masking via polymer film-coating or lipid barrier systems; and (iii) biochemical masking via intermolecular interaction, β-cyclodextrin inclusion, or ion-exchange resins. This review fully summarizes the results reported in this field with the purpose of providing an informative reference for relevant readers.Entities:
Keywords: bitterness; compliance; taste-masking techniques; traditional Chinese medicine
Year: 2018 PMID: 30213035 PMCID: PMC6161181 DOI: 10.3390/pharmaceutics10030157
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Improvement of patient acceptability of traditional Chinese medicine (TCM) systems via three types of taste-masking techniques.
Taste-masking of substances derived from traditional Chinese medicine via functional masking.
| Types | Masking Agents | Masked Substances | Improved Properties | References |
|---|---|---|---|---|
| Adding sweeteners | Aspartame; saccharine sodium | Quinine | The bitterness score ↓ 87%, the perceived bitterness further ↓ as the amount of aspartame ↑; CPA value not changed | [ |
| Sucrose plus inositol | Aristolochic acid | The biting number of | [ | |
| Stevioside | Decoction of | The decoctions: bitter value ↓ 0.58–1.26 fold, bitter level from IV to III, bitterness ↓ 14.0–30.5% | [ | |
| Neohesperidosyl dihydrochalcone | Decoction of | The decoctions: bitter value ↓ 0.44–1.50 fold, bitter level from IV to III, bitterness ↓ 10.65–36.32% | [ | |
| Neotame | Decoction of | The bitterness of such decoctions ↓ 70.11%, ↓ 49.12%, ↓ 71.88%, ↓ 50.87%, ↓ 38.39%, respectively; the bitter value ↓ 1.22-fold, ↓ 1.78-fold, ↓ 1.77-fold, ↓ 2.02-fold, ↓ 1.43-fold, respectively | [ | |
| Adding bitter blockers | MR15, 234A, MZ70, and 6100 | Bitter melon | The content of momordicosides K and L treated with such blockers was not changed | [ |
| Gingerdione derivatives | Quinine | The bitterness of quinine ↓ about 20%; the sucrose equivalents of sucrose ↑ about 0.4–1.6% | [ | |
| Adding taste modifiers | Trans-pellitorine | EGCG | The absolute astringency of EGCG ↓ 18–33%; the absolute bitterness ↓ 3–23%. | [ |
| Caffeine, theobromine, and cyclo (L-Pro–L-Val) | Ginseng | The sweetness value ↓ ~70% | [ |
Note: CPA, the change in the membrane potential caused by adsorption; EGCG, epigallocatechin-3-gallate.
Figure 2The chemical structures of taste-masking agents involved in functional masking.
Taste-masking of substances derived from traditional Chinese medicine via physical masking.
| Types | Coating Material | Masked Substances | Dosage Form | Formulation Composition | Preparation Method | Improved Properties | References |
|---|---|---|---|---|---|---|---|
| Polymer film-coating | Opadry® enteric | Dihydroartemisinin | Granules | Dihydroartemisinin, carbopol, sodium metabisulphite, methyl paraben sodium (14:1:2:3 mass ratio) plus distilled water and Opadry® enteric | Using conventional coating pans | The Opadry® enteric-coated granules: in vitro dissolution of bitter dihydroartemisinin ↓~50% in pH of 6.8; thermal stability of coated granules close to the pure granules | [ |
| Opadry® enteric | Artemether | Particles of dry suspension | Artemether, carbopol 934P, sodium metabisulphite, methyl paraben sodium (7:5:12:16 mass ratio) plus distilled water, Opadry® enteric, sugar fine, aerosil, xanthan gum, tit. Dioxide, orange flavor, NaCl, and citric acid | Using conventional coating pans | The Opadry® enteric-coated particles of dry suspension: in vitro dissolution of bitter artemether ↓ ~50% in pH of 6.8, the bitter taste intensity score of artemether ↓ ~55% | [ | |
| Acrylic resin II | Coptis Chinensis | Granules | Coptis Chinensis:starch, microcrystalline cellulose:lactose, Acrylic resin II, aspartame, PEG6000, talc powder | Using conventional coating pans | The coated granules: bitterness ↓; moisture-proof ability ↑ | [ | |
| Eudragit E100 | Andrographitis compound particle | Suspension particles | Sucrose, 10% starch slurry, Andrographitis compound particle, Eudragit E100 | Using fluidized bed systems | The coated suspension particles: mouthfeel ↑; dispersed uniformly in water | [ | |
| Eudragit® E PO | Quinine sulfate | Pellets | Eudragit® E PO, quinine sulphate pellets, sodium lauryl sulphate, stearic acid, magnesium stearate | Using fluidized bed systems | The coated pellets: in vitro release in water ↓ ~34–85% than uncoated pellets; in vivo AUC0–24h ↑ 0.16-fold, Cmax ↑ 0.27-fold compared to commercial tablets | [ | |
| Eudragit E100 | Artemether | Microparticles | Eudragit E100, artemether, sodium hydroxide | Using a coacervation phase separation method | The microparticles: high drug loading; rapid release at pH 1.2, release ↓ ~13% in 1 h at pH 6.8; the bitterness score ↓ at pH 6.8 | [ | |
| Eudragit E100 | Berberine | Microcapsules | Berberine hydrochloride, Eudragit E100 | Using fluidized bed systems | The microcapsules: nearly 80% dissolved in 0.1 mol/L HCl in 30 min, whereas only ~1% in water in 1 h | [ | |
| Eudragit E100 | Berberine | Orally disintegrating tablet | Berberine hydrochloride, Eudragit E100, 6% ( | The ODTs: faster release of the drug than commercial tablets within the initial 10 min in HCl; at 5 min, the percentage of drug release ↑ 1.5-fold compared to common tablets; bioequivalent to the commercial tablets; stable throughout storage of 6 months | [ | ||
| Chitosan | Artemether | Microparticles | Artemether, chitosan and sodium hydroxide were 0.056 g, 0.03 g and 15 mL | _ | The microparticles: the release at pH 6.8 ↓; the release ↓ as the quantity of crosslinking agent ↑ | [ | |
| Alginate/chitosan complex | Alcohol extract of the fruit of | Microcapsules | 2.50% alginate solution 0.25% Tween 80 ( | Using a complex coacervation method | The microcapsules: high encapsulation efficiency; mass loss of 80.40% compared to 99.89% of the fraction alone at 500 °C; 53.85% released at pH = 1.2, 22.03% released at pH = 6.8 | [ | |
| Lipid barrier systems | Carnauba wax | Quercetin | Powders | 70% quercetin, 30% carnauba wax/shellac | Using hot-melt extrusion | The powders: dissolution ↓ 0.8-fold compared to the free drug in the oral cavity; the bitterness sensory output ↓ 80%; similar release profile with the free drug | [ |
| HPMC, lecithin, isomalt | Curcumin | Solid dispersion | Curcumin, HPMC, lecithin, isomalt (2:15:2:1) | Using hot-melt extrusion | The solid dispersion: Cmax ↑ 5.8-fold, AUC0–∞ ↑ 11.8-fold, Tmax ↑ 2.9-fold compared to the free drug; enhanced anti-inflammatory bioactivity at 10-fold lower dose | [ | |
| Vegetable fat | Proanthocyanidin-rich cinnamon extract | Solid lipid microparticles | Proanthocyanidin-rich cinnamon extract, vegetable fat (8:72) | Using spray chilling technique | The solid lipid microparticles: ↑ stability; masked the taste of bitterness and astringency | [ | |
| Glyceryl monostearate | Quinine sulphate | Solid lipid nanoparticles | Glyceryl monostearate, drug (3:1) + 2% poloxamer 188 | Using ultrasonic solvent emulsification technique | The solid lipid nanoparticles: provided accurate dosage to children; quickly released in pH 1.2; ↓ ~100-fold release in pH 6.8 | [ |
Note: AUC, area under the concentration–time curve; Cmax, maximum plasma concentration; ODTs, orally disintegrating tables; HPMC, hydroxypropyl methyl cellulose; Tmax, time to reach Cmax; FHPp: the fruit of Pterodon pubescens Ben.
Taste-masking of substances derived from traditional Chinese medicine via biochemical masking.
| Types | Complexing Agents | Masked Substances | Preparation Method | Improved Properties | Reference |
|---|---|---|---|---|---|
| Intermolecular interaction | β-casein | EGCG | Using ultrafiltration method | The complexes: ↓ 72.8% of the activation of hTAS2R39; binding affinity ↑, maximal binding capacity ↑; the bitterness score ↓ 3 | [ |
| β-lactoglobulin | Allicin | - | The complexes: taste intensity ↓ 3, DADS abundance ↓ 1300 | [ | |
| Sodium laurate | Quinine | - | The binary insoluble complexes ↓ bitter taste | [ | |
| β-cyclodextrin inclusion | β-cyclodextrin | Artemether | Using physical mixing method | The inclusion complexes: solubility ↑ 3-fold, the release in pH 6.8 ↑ 0.76-fold, the release in pH 1.2 ↑ 6.79-fold; the bitterness score ↓ 3 | [ |
| β-cyclodextrin plus Eudragit® E PO | Thymol | Using sealed-heating method | The complexes: volatility ↓ 96.6%; release rate ↑ 7-fold in gastrointestinal fluid, in vitro dissolution rate ↑; Tmax ↓ 1.29-fold, in vivo absorption rate ↑ | [ | |
| β-cyclodextrin | Decoction of | Using physical mixing method | The level of bitterness of | [ | |
| β-cyclodextrin | Liu-She powder | Using colloid grinding method | The inclusion complexes: relative distance ↑ 59, the inclusion rates of | [ | |
| Ion-exchange resins complexation | Amberlite IRA-400 | Using electrostatic attraction method | The resin complexes ↓ bitterness | [ | |
| AmberliteTM IRP88 | Quinine | Using electrostatic attraction method | The time of quinine adsorbed by the resin ↓ compared to INDION 234 and AmberliteTM IRP69; the drug amount constantly decreased during binding to this resin | [ |
Note: EGCG, epigallocatechin-3-gallate; DADS, diallyl disulfide.